DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007

Wednesday, February 20, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CLEVELAND, Feb. 19 DATATRAK International, Inc.(Nasdaq: DATA), a technology and services company focused on global eClinicalsolutions for the clinical trials industry, today announced that it will hosta conference call to discuss fourth quarter and full year operating resultsfor 2007 at 4:30 p.m. ET on Tuesday, February 26, 2008.

To participate via phone, participants are asked to dial 412-858-4600 afew minutes before 4:30 p.m. ET. The conference call will also be availablevia live web cast on DATATRAK International, Inc.'s web site by clicking thebutton labeled "Click here for Live Web Cast, 4th Quarter Earnings Call" onthe Company's homepage at a few minutes before 4:30 p.m. ET.

A replay of the phone call and web cast will each be available atapproximately 6:30 p.m. ET on February 26, 2008 and will run until 9:00 a.m.ET on March 4, 2008. The phone replay can be accessed by dialing 412-317-0088(access code 416290). To access the web cast replay go to the Company'shomepage at and click the button labeled "Click here forReplay of Web Cast, 4th Quarter Earnings Call."

DATATRAK International, Inc. is a worldwide technology company focused onthe provision of multi-component eClinical solutions and related services forthe clinical trials industry. The Company delivers a complete portfolio ofsoftware products that were created in order to accelerate clinical researchdata from investigative sites to clinical trial sponsors and ultimately theFDA, faster and more efficiently than manual methods or loosely integratedtechnologies. DATATRAK's eClinical software suite can be deployed worldwidethrough an ASP offering or in a licensed Enterprise Transfer model that fullyempowers its clients. The DATATRAK software suite and its earlier versionshave successfully supported hundreds of international clinical trialsinvolving thousands of clinical research sites and encompassing tens ofthousands of patients in 59 countries. DATATRAK International, Inc.'s productsuite has been utilized in some aspect of the clinical development of 16separate drugs and one medical device that have received regulatory approvalfrom either the United States Food and Drug Administration or counterpartEuropean bodies. DATATRAK International, Inc. has offices located inCleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listedon the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAKInternational, Inc. web site at

Except for the historical information contained in this press release, thestatements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations and beliefsconcerning future events impacting the Company and are subject touncertainties and factors (including those specified below) which aredifficult to predict and, in many instances, are beyond the control of theCompany. Factors that may cause actual results to differ materially from thosein the forward-looking statements include the limited operating history onwhich the Company's performance can be evaluated; the ability of the Companyto continue to enhance its software products to meet customer and marketneeds; fluctuations in the Company's quarterly results; the viability of theCompany's business strategy and its early stage of development; the timing ofclinical trial sponsor decisions to conduct new clinical trials or cancel ordelay ongoing trials; the Company's dependence on major customers; governmentregulation associated with clinical trials and the approval of new drugs; theability of the Company to compete in the emerging EDC market; losses thatpotentially could be incurred from breaches of contracts or loss of customerdata; the inability to protect intellectual property rights or theinfringement upon other's intellectual property rights; the Company's

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store